Collegium Pharmaceutical
COLL · Pharmaceuticals
$22.96
2.3%Indivior
INDV · Pharmaceuticals
$34.47
2.4%The short version
- Indivior is the larger business, with $1.2B of revenue in fiscal 2025 against $781M for Collegium Pharmaceutical, about 1.6 times as much.
- Collegium Pharmaceutical grew revenue faster (23.6%, against 4.3%).
- Collegium Pharmaceutical kept more of each dollar of sales as operating profit (23.0% operating margin, against 21.2% operating margin).
- Collegium Pharmaceutical turned more of its sales into free cash flow (42.0% FCF margin, against −7.5% FCF margin).
- Investors pay more for each dollar of Collegium Pharmaceutical’s earnings: a P/E of 18.5x against 12.4x for Indivior.
| Latest fiscal year | COLL · FY25 | INDV · FY25 |
|---|---|---|
| Size | ||
| Market cap | $746M | $4.3B |
| Revenue | $781M | $1.2B |
| Free cash flow | $328M | −$93.0M |
| Net income | $62.9M | $210M |
| Growth | ||
| Revenue growth | 23.6% | 4.3% |
| 5-year growth | 20.3% | — |
| Share count change | −1.8% | −3.8% |
| Profitability | ||
| Gross margin | 59.4% | 80.2% |
| Operating margin | 23.0% | 21.2% |
| Net margin | 8.1% | 17.0% |
| FCF margin | 42.0% | −7.5% |
| Return on capital | 53.4% | — |
| Return on equity | 23.7% | — |
| Balance sheet | ||
| Net debt | −$149M | $124M |
| Net debt / EBITDA | −0.4x | 0.5x |
| Dividends and buybacks | $25.1M | $11.0M |
| Valuation & quality | ||
| P/E | 18.5x | 12.4x |
| Piotroski F-score | 6 | 4 |
FY16
COLL $1.7M
INDV —
FY17
COLL $28.5M
INDV —
FY18
COLL $280M
INDV —
FY19
COLL $297M
INDV —
FY20
COLL $310M
INDV —
FY21
COLL $277M
INDV $791M
FY22
COLL $464M
INDV $901M
FY23
COLL $567M
INDV $1.1B
FY24
COLL $631M
INDV $1.2B
FY25
COLL $781M
INDV $1.2B
COLL
INDV
FY16
COLL −5,498.7%
INDV —
FY17
COLL −265.0%
INDV —
FY18
COLL −7.4%
INDV —
FY19
COLL −8.0%
INDV —
FY20
COLL 18.1%
INDV —
FY21
COLL 6.4%
INDV 26.9%
FY22
COLL 7.2%
INDV −9.0%
FY23
COLL 29.5%
INDV −13.9%
FY24
COLL 26.9%
INDV 3.2%
FY25
COLL 23.0%
INDV 21.2%
COLL
INDV
FY16
COLL −$75.5M
INDV —
FY17
COLL −$68.0M
INDV —
FY18
COLL $164M
INDV —
FY19
COLL $21.3M
INDV —
FY20
COLL $88.4M
INDV —
FY21
COLL $102M
INDV $349M
FY22
COLL $123M
INDV −$9.0M
FY23
COLL $274M
INDV −$308M
FY24
COLL $203M
INDV $7.0M
FY25
COLL $328M
INDV −$93.0M
COLL
INDV
FY16
COLL —
INDV —
FY17
COLL —
INDV —
FY18
COLL —
INDV —
FY19
COLL —
INDV —
FY20
COLL —
INDV —
FY21
COLL 10.4%
INDV —
FY22
COLL 16.5%
INDV —
FY23
COLL 68.7%
INDV —
FY24
COLL 53.0%
INDV —
FY25
COLL 53.4%
INDV —
COLL
INDV
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.